Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (11-20 of 274) with videos related to

Pageof 28
Sort By:
Expert Opinion on Drug Safety|November 27, 2015
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluationDaisuke Yabe, Yutaka Seino
The Journal of Clinical Endocrinology and Metabolism|January 17, 2024
Visceral Adipose Tissue Quality and its Impact on Metabolic HealthSodai Kubota, Daisuke Yabe
Nutrients|October 28, 2023
Dietary and Nutritional Guidelines for People with DiabetesKatsumi Iizuka, Daisuke Yabe
Expert Review of Endocrinology & Metabolism|February 10, 2019
Alogliptin for the treatment of Type 2 diabetesYutaka Seino, Daisuke Yabe
Expert Review of Endocrinology & Metabolism|February 10, 2019
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetesDaisuke Yabe, Yutaka Seino
The Journal of Clinical Endocrinology and Metabolism|May 5, 2021
Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?Sodai Kubota, Daisuke Yabe
The Lancet. Diabetes & Endocrinology|November 19, 2015
Type 2 diabetes via β-cell dysfunction in east Asian peopleDaisuke Yabe, Yutaka Seino
Current Opinion in Pharmacology|October 8, 2013
Incretin actions beyond the pancreas: lessons from knockout miceDaisuke Yabe, Yutaka Seino
Journal of Diabetes Investigation|May 21, 2014
Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic controlDaisuke Yabe, Yutaka Seino
Journal of Diabetes Investigation|May 21, 2014
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreasYutaka Seino, Daisuke Yabe
Pageof 28

Showing results (11-20 of 274) with videos related to

Sort By:
Pageof 28
Expert Opinion on Drug Safety|November 27, 2015
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluationDaisuke Yabe, Yutaka Seino
The Journal of Clinical Endocrinology and Metabolism|January 17, 2024
Visceral Adipose Tissue Quality and its Impact on Metabolic HealthSodai Kubota, Daisuke Yabe
Nutrients|October 28, 2023
Dietary and Nutritional Guidelines for People with DiabetesKatsumi Iizuka, Daisuke Yabe
Expert Review of Endocrinology & Metabolism|February 10, 2019
Alogliptin for the treatment of Type 2 diabetesYutaka Seino, Daisuke Yabe
Expert Review of Endocrinology & Metabolism|February 10, 2019
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetesDaisuke Yabe, Yutaka Seino
The Journal of Clinical Endocrinology and Metabolism|May 5, 2021
Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?Sodai Kubota, Daisuke Yabe
The Lancet. Diabetes & Endocrinology|November 19, 2015
Type 2 diabetes via β-cell dysfunction in east Asian peopleDaisuke Yabe, Yutaka Seino
Current Opinion in Pharmacology|October 8, 2013
Incretin actions beyond the pancreas: lessons from knockout miceDaisuke Yabe, Yutaka Seino
Journal of Diabetes Investigation|May 21, 2014
Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic controlDaisuke Yabe, Yutaka Seino
Journal of Diabetes Investigation|May 21, 2014
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreasYutaka Seino, Daisuke Yabe
Pageof 28